Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CA9-H82E3 | Human | Biotinylated Human Carbonic Anhydrase IX / CA9 (38-414) Protein, His,Avitag™ | ![]() |
||
CA9-H5220 | Human | Human Carbonic Anhydrase IX / CA9 (138-414) Protein, His Tag | ![]() |
![]() ![]() |
|
CA9-H5226 | Human | Human Carbonic Anhydrase IX / CA9 (38-414) Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Lutetium-177 DOTA girentuximab | Phase 2 Clinical | Telix Pharmaceuticals, Heidelberg, Wilex | Carcinoma, Renal Cell | Details | |
PMI-05 | PMI-05 | Phase 1 Clinical | Precision Molecular | Neoplasms | Details |
Sulfamide-nitroimidazole | Clinical | Dualtpharma | Neoplasms | Details | |
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) | Phase 1 Clinical | Radboud University Nijmegen | Carcinoma, Renal Cell; Diagnostic agents | Details |
This web search service is supported by Google Inc.